Cellectar Biosciences Inc Asset Resilience Ratio
Cellectar Biosciences Inc asset resilience ratio. Cellectar Biosciences Inc (CLRB) has an Asset Resilience Ratio of 0.28% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CLRB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cellectar Biosciences Inc (2010–2018)
Asset resilience ratio of Cellectar Biosciences Inc from 2010 to 2018. This chart shows how Cellectar Biosciences Inc's Asset Resilience Ratio has changed over time. Read CLRB liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cellectar Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CLRB total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $55.00K | 0.28% |
| Total Liquid Assets | $55.00K | 0.28% |
Asset Resilience Insights
- Limited Liquidity: Cellectar Biosciences Inc maintains only 0.28% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cellectar Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Cellectar Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Cellectar Biosciences Inc Asset Resilience Ratio by Year (2010–2018)
Cellectar Biosciences Inc asset resilience ratio by year from 2010 to 2018. The table below shows the annual Asset Resilience Ratio data for Cellectar Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.37% | $55.00K | $15.05 Million | -0.06pp |
| 2017-12-31 | 0.43% | $55.00K | $12.87 Million | +0.07pp |
| 2016-12-31 | 0.36% | $55.00K | $15.32 Million | -0.37pp |
| 2015-12-31 | 0.72% | $55.00K | $7.60 Million | +0.31pp |
| 2014-12-31 | 0.41% | $55.00K | $13.42 Million | -0.40pp |
| 2013-12-31 | 0.81% | $55.00K | $6.82 Million | +0.33pp |
| 2012-12-31 | 0.48% | $55.00K | $11.48 Million | -0.04pp |
| 2011-12-31 | 0.52% | $55.00K | $10.56 Million | -22.03pp |
| 2010-12-31 | 22.56% | $555.00K | $2.46 Million | -- |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more